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Cardiotoxicity is a well-known and potentially 
serious complication of anticancer therapy that can 
significantly impair patient’s quality of life and also 
substantially increase health care costs. The greatest 
risk for development of cardiotoxicity represent an-
thracyclines (ANT) [1–3] and high-dose chemotherapy 
(HD-CT) especially regimens containing high-dose 
cyclophosphamide [4–6]. Various methods have 
been recommended for monitoring of cardiotoxicity 
in oncology [7, 8]. In our conditions, echocardiogra-
phy and electrocardiography are routinely used [9, 
10]. Recently, biochemical markers of cardiac injury, 
especially cardiac troponins and natriuretic peptides, 
have been investigated in the assessment of cancer 
therapy-induced cardiotoxicity [11–13].
Cardiac troponins — cardiac troponin T (cTnT), 
cardiac troponin I (cTnI) — and myocardial izoenzyme 
of creatine kinase (CK-MB) are cardiospecific markers 
that show structural injury of cardiomyocytes from va-
rious causes, including cardiotoxic effect of anticancer 
therapy [14–17].
Heart-type fatty acid binding protein (H-FABP) 
and glycogen phosphorylase isoenzyme BB (GPBB) 
are new perspective markers of myocardial ischemia 
and necrosis, recently evaluated in the diagnostics 
and risk stratification of acute coronary syndromes 
[18–22]. H-FABP is a relatively small cytoplasmic pro-
tein for the oxidation of fatty acids that is quite specific 
for cardiac muscle. H-FABP is rapidly released from 
the myocardium into the bloodstream after ischemic 
injury. Plasma H-FABP increases above the reference 
limit within 2–3 h of the onset of myocardial injury and 
returns to normal within 18–30 h. GPBB is a glyco-
genolytic enzyme providing glucose for heart muscle 
tissue. After glycogenolysis in ischemic tissue, GPBB 
is released from the sarcoplasmic reticulum into the 
cytoplasm and then into the circulation through the 
damaged cell membrane. GPBB is released into the 
circulation 2–4 h after myocardial injury, returning to 
normal va lues within 24–36 h of damage occurring. 
In the acute coronary syndrome setting, both markers 
are regarded early markers of cardiac injury due to 
acute myocardial ischemia. However, the main mecha-
nism of cardiac injury caused by anticancer therapy is 
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mainly non-ischemic and prior cyclic exposition to ANT 
agents may play a role (chronic and late cardiotoxici-
ty). Therefore, it is difficult to estimate the kinetics of 
release of these biomarkers from cardiomyocytes in 
this setting. At present, new perspective biomarkers 
of cardiotoxicity have been evaluated inadequately in 
patients treated for oncological diseases.
The aim of our study was to evaluate cardiac toxi city 
of conventional CT containing ANT and HD-CT followed 
by hematopoietic cell transplantation (HCT) with mul-
tiple biomarkers of cardiac injury: glycogen phosphory-
lase BB (GPBB), heart-type fatty acid binding protein 
(H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase 
MB (CK-MB mass), myoglobin. Experience with GPBB 
and H-FABP in this context is very limited.
PATIENTS AND METHODS 
A total of 47 patients treated for acute leukemia 
were included in the study. The study population was 
divided into 2 groups — (1) 24 patients treated with 
conventional CT containing ANT (3–6 cycles of CT, 
mean total cumulative ANT dose 463.2 ± 114.3 mg/m2), 
mean age 48.1 ± 10.9 years, 13 males. All patients had 
de novo acute myeloid leukemia (AML): 2 — AML M1, 
16 — AML M2, 5 — AML M4, 1 — AML M5 according 
to FAB classification; (2) 23 patients treated with HD-
CT (ablative preparative regimen containing high-dose 
cyclophosphamide in the total dose of 120 mg/kg in 
combination with peroral busulfan 16 mg/kg /BuCy2/ 
or fractionated total body irradiation 12 Gy /CyTBI/) fol-
lowed by HCT, mean age of 44.5 ± 10.6 years, 15 males. 
Twenty patients had AML, from that 2 — AML M1, 14 — 
AML M2, 4 — AML M4 according to FAB classification, 
and 3 patients had acute lymphoblastic leukemia (ALL), 
from that 2 — B-ALL, 1 — T-ALL. All patients had normal 
liver and renal functions during the study. The study was 
carried out with approval from the ethics committee. 
All patients gave a written consent before they were 
included in the study.
In the first group, biochemical analysis was per-
formed at the baseline (before CT), the day after first 
CT with ANT (after first CT; mean cumulative ANT dose 
130.6 ± 29.8 mg/m2), the day after last CT with ANT (af-
ter last CT; mean cumulative dose 463.2 ± 114.3 mg/m2). 
In the second group, cardiac biomarkers were assessed 
the day before administration of HD-CT (before HD-CT), 
the day after completion of HD-CT (after HD-CT) and 
the day after HCT (after HCT).
Circulating biomarkers of cardiac injury were 
measured according to the manufacturer’s guidelines 
as follows: cTnT, CK-MB mass, myoglobin (Roche 
Diagnostics; Elecsys analyzer), GPBB, H-FABP, cTnI 
(Randox; Evidence Investigator analyzer).
Concentrations of cardiac biomarkers diagnostic 
for cardiotoxicity of oncology treatment have not been 
established yet. On that ground, values above the refe-
rence range based on a number of cardiology studies 
and recommended by the manufacturers were consi-
dered elevated. The cut-off values for cardiac injury 
were as follows: 7.30 μg/L for GPBB, 4.50 μg/L for 
H-FABP, 0.40 μg/L for cTnI, 0.01 μg/L for cTnT, 4.80 μg/L 
for CK-MB mass and 76.0 μg/L for myoglobin.
RESULTS
The cut-off values of all biomarkers and the number of 
patients with elevated values are shown in Table 1 and 2.
Table 1. Elevated biomarkers of cardiac injury in association with 
anthracycline-based chemotherapy (n = 24)
Cardiac biomarkers Before CT After first CT After last CT
Myoglobin above 76.0 μg/L 0 0 0
CK-MB mass above 4.80 μg/L 0 0 0
cTnT above 0.01 μg/L 0 0 0
cTnI above 0.40 μg/L 0 2 (8.3%) 2 (8.3%)
H-FABP above 4.50 μg/L 0 0 0
GPBB above 7.30 μg/L 0 4 (16.7%) 5 (20.8%)
In Table 1 and 2: CT — chemotherapy; HD-CT — high-dose chemotherapy; 
HCT — hematopoietic cell transplantation; CK-MB mass — creatine kinase 
MB; cTnT — cardiac troponin T; cTnI — cardiac troponin I; H-FABP — heart-
type fatty acid binding protein; GPBB — glycogen phosphorylase BB.
Table 2. Elevated biomarkers of cardiac injury in association with high-
dose chemotherapy and hematopoietic cell transplantation (n = 23)
Cardiac biomarkers Before HD-CT After HD-CT After HCT
Myoglobin above 76.0 μg/L 0 0 0
CK-MB mass above 4.80 μg/L 0 0 0
cTnT above 0.01 μg/L 0 0 0
cTnI above 0.40 μg/L 0 0 0
H-FABP above 4.50 μg/L 0 0 0
GPBB above 7.30 μg/L 0 5 (21.7%) 5 (21.7%)
Before CT/HD-CT, all biomarkers of cardiac injury 
were below the cut-off values in all patients. GPBB con-
centrations increased above the cut-off in 4 (16.7%) 
patients after first CT and in 5 (20.8%) patients after 
last CT with ANT. In the second group, GPBB increased 
above the cut-off in 5 (21.7%) patients after HD-CT and 
remained elevated in 5 (21.7%) patients after HCT. CTnI 
concentrations became elevated in 2 (8.3%) patients 
after first and last CT with ANT. Both patients with cTnI 
positivity had elevated GPBB. CTnI remained nega-
tive after HD-CT and HCT in all patients. Other tested 
biomarkers (H-FABP, cTnT, CK-MB mass, myoglobin) 
remained below the cut-offs during conventional CT 
containing ANT and HD-CT followed by HCT.
DISCUSSION
GPBB and H-FABP have been recently investi-
gated in the early detection of cardiac injury. They 
have been suggested sensitive markers of myocardial 
ischemia and necrosis in patients with acute coronary 
synd romes [18–22]. Moreover, GPBB could be as-
sociated with pulmonary artery wedge pressure and 
left ventricle mass index in patients with hypertrophic 
cardiomyopathy. This finding raises an important is-
sue concerning the role of cardiac biomarkers in the 
diagnosis of hypertrophic cardiomyopathy and could 
potentially provide a useful tool to stratify these 
patients [23]. However, in the field of cardiotoxicity 
of anticancer therapy, these perspective biomarkers 
of cardiac injury have been evaluated inadequately. 
In 2008, we published our pilot study on usability 
of multiple biomarkers, including GPBB and H-FABP, 
for evaluation of ANT-induced cardiotoxicity in patients 
with acute myeloid leukemia [24]. Recently, we applied 
multiple biomarkers, including GPBB and H-FABP, 
in the assessment of cardiotoxicity associated with 
administration of preparative regimen and HCT for 
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various hematological malignancies [25]. ElGhan-
dour et al. [26] studied H-FABP in 40 non-Hodgkin’s 
lymphoma patients treated with 6 cycles of CT contain-
ing doxorubicin (cumulative dose 300 mg/m2). The 
 authors concluded that H-FABP may serve as a reliable 
early marker for prediction of cardiomyopathy induced 
by doxorubicin. Otherwise, no studies have been 
published so far and experience with these perspec-
tive biomarkers in the assessment of cardiotoxicity 
of anticancer therapy is very limited.
In our present study on 47 acute leukemia patients, 
we found significant elevations in GPBB after CT with 
ANT (in 16.7% and 20.8% patients, respectively) and 
after HD-CT followed by HCT (in 21.7% patients). In-
creased release of GPBB from cardiomyocytes after 
administration of CT could be considered a sign of acute 
subclinical cardiotoxicity of this treatment. Positivity of 
GPBB in patients with negativity of other biomarkers 
(cTnI, cTnT, H-FABP, CK-MB mass, myoglobin) sug-
gests that GPBB could be a more sensitive marker for 
detection of acute cardiac injury caused by anticancer 
therapy, both conventional and HD-CT. Whether these 
acute changes will have predictive value for develop-
ment of CT-associated cardiomyopathy in the future is 
not clear and should be evaluated during a prospective 
follow-up. Based on our data, a larger prospective and 
multicenter study would be most desirable to define 
the potential role of new circulating biomarkers in the 
assessment of cardiotoxicity in oncology.
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